Dr Jeff Sherer, who owns dental practices in Lincolnshire and the Humber region, said he referred one or two patients a week for potential cases of oral cancer. He added: "When patients can't access a ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...

PVEK, a CD123-targeting antibody-drug conjugate, demonstrated strong response rates in two studies. Combined with VEN/AZA, it ...

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case ...

Patients who have metastatic chromophobe renal cell carcinoma (ChrRCC) that harbors sarcomatoid features (SF) benefited from immunotherapy (IO)-containing regimens vs patients wit ...

Early symptoms of neuroblastoma are similar to other common diseases. However, this disease is not a common disease, but a rare type of cancer that begins to grow while the baby is still in the womb ...

Pneumonia and lung cancer present similar symptoms like cough and chest pain. Pneumonia is a rapid infection, while lung ...

The time of day that cancer drugs are administered could make a big difference to a patient's outcomes, and would be a ...

Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or ...

Platelet-to-Lymphocyte Ratio (PLR): Elevated PLR is another key marker linked to more aggressive tumor characteristics, such ...

Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...

Clinicians Laura Huppert, Kelsey Natsuhara, and Magdelena Ford discuss the evidence, challenges, and real-world ...